Business Context and Reporting Period
This Form 8-K is filed by Elevai Labs Inc. (not PMGC Holdings Inc. as indicated in metadata) for the reporting period ending March 1, 2024. The registrant is an emerging growth company incorporated in Delaware, with its common stock (Symbol: ELAB) listed on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to director compensation:
- Director Compensation: 80,000 non-statutory stock options granted to Mr. George Kovalyov with an exercise price of $1.00 per share.
Material Changes
Nasdaq Listing Compliance
On March 6, 2024, the Company received notice from Nasdaq that it failed to meet the Minimum Bid Price Requirement of $1.00 per share for 30 consecutive trading days. The stock remains listed, but the Company has an initial 180-day compliance period to regain compliance (deadline: September 3, 2024). Failure to comply may result in delisting.
Board of Directors Changes
- Resignation: Ms. Crystal Muilenburg resigned as an independent director and chair of the Compensation Committee effective March 1, 2024, citing limited availability due to other commitments. The resignation was not due to any dispute with the Company.
- Appointment: Mr. George Kovalyov was appointed as an independent director, member of the Audit and Nominating Committees, and Chairman of the Compensation Committee on March 6, 2024.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and consider available options to resolve the Nasdaq noncompliance. The filing explicitly states there is no assurance that the Company will regain compliance or that Nasdaq will grant further extensions. If compliance is not achieved, the stock may be delisted, though the Company retains the right to appeal to a Nasdaq Listing Qualifications Panel.
Investor Verification Checklist
- Verify the current trading price of ELAB to assess the likelihood of meeting the $1.00 bid price requirement by September 3, 2024.
- Review the Company's subsequent filings for any reverse stock split proposals or other capital structure changes intended to cure the bid price deficiency.
- Confirm the full text of the Director Offer Letter (Exhibit 10.1) for details on Mr. Kovalyov's incentive payments beyond the stock options.
- Monitor for any further announcements regarding the composition of the Board of Directors following the resignation of Ms. Muilenburg.